Positions
- Professor
-
Medicine-Nephrology
vlog of Medicine
Houston, TX, US
Education
- B.Sc. from Hebrew University Of Jerusalem
- 01/1976 - Jerusalem, Israel
- M.D. from Hadassah Medical School
- 01/1981 - Jerusalem, Israel
- Advanced Training from University Of California, Los Angeles
- 01/1984 - Los Angeles, CA, United States
- Advanced Training from National Institutes Of Health
- 01/1991 - Bethesda, MD, United States
Certifications
- ABIM-Nephrology
- #115454
- ABIM
- Re-certified 2002
- ABIM-Medicine
- #115454
- ABIM
- Valid indefinitely
Honors & Awards
- Fulbright & Jaworski L. L. P. Faculty Excellence Award
- Recipient of vlog of Medicine Fulbright & Jaworski L. L. P. Faculty Excellence Award for Teaching and Evaluation (8/2007).
- vlog of Medicine (08/2007)
- Award for Excellence in Teaching
- Award for Excellence in Teaching (2001-2002): Department of Medicine, vlog of Medicine.
- BCM (07/2002)
- Elected Member, Leadership Committee of KCVD
- Member at-Large (Elected): Leadership Committee of the Council on the Kidney in Cardiovascular Disease (KCVD); AHA, 7/2005 - 2010.
- AHA (07/2005)
- Member, Nominating Committee, KCVD
- Member: Nominating Committee of the AHA Council on Kidney in Cardiovascular Disease (KCVVD), 2004-2010.
- AHA (07/2004 - 06/2010)
- Member of the Academy of Distinguished Educators
- Member of the Academy of Distinguished Educators, vlog of Medicine (8/2007)
- BCM (07/2007)
Professional Interests
- Riverside Clinic
- Kidney Protection via Metabolic Sensors
Websites
Publications on PubMed
Professional Development
- Renal Grand Rounds
- Conference (Organizer, 2009)
- Sponsor: BCM/Methodist Hospital
- Weekly conference presented by national and international nephrology leaders, and features state-of-the-art lectures and new advances in nephrology.
Selected Publications
-
http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/?term=sheikh-hamad. " ;
-
Christensen BM, Marples D, Jensen UB, Frokiaer J, Sheikh-Hamad D, Knepper M, Nielsen S. " " Am. J. Physiol.. 1998 Aug ; 275 (2) : F285-97.
Pubmed PMID: . -
Morduchowicz GA, Sheikh-Hamad D, Dwyer BE, Stern N, Jo OD, Yanagawa N. " " J. Membr. Biol.. 1991 May ; 122 (1) : 43-53.
Pubmed PMID: . -
Huang L, Garcia G, Lou Y, Zhou Q, Truong LD, DiMattia G, Lan XR, Lan HY, Wang Y, Sheikh-Hamad D. " " Am. J. Pathol.. 2009 Apr ; 174 (4) : 1368-78.
Pubmed PMID: .
Funding
-
Stanniocalcin-1: New paradigms for cytoprotection and anti-inflammation
#I01BX002006 - $600,000.00 (04/01/2014 - 09/30/2018)
- Grant funding from Veteran Administration
- Reactive oxygen species (ROS), endothelial injury and macrophages play critical roles in ischemia/reperfusion (I/R) kidney injury. Our data show stanniocalcin-1 (STC1) diminishes superoxide generation in macrophages, through induction of uncoupling protein-2 (UCP2), decreases the response of macrophages to chemoattractants- and migration across an endothelial monolayer. In cultured endothelial cells, STC1 preserve barrier function. STC1: diminishes superoxide generation; inhibits cytokine-induced activation of Jun-N-terminal kinase (JNK) and loss of tight junction proteins expression. STC1 transgenic mice, which exhibit elevated serum levels and preferential expression of STC1 in macrophages and endothelium, display resistance to I/R kidney injury. Overall hypothesis: STC1 protects from I/R kidney injury through: suppression of superoxide generation; maintenance of normal endothelial barrier function following I/R kidney injury; and inhibition of macrophages. In Objective I, we will determine the role of superoxide and Daxx in STC1-mediated inhibition of JNK in endothelial cells. In Objective II, we will determine the effect of STC1 on hypoxia/reoxygenation (H/RO)-induced changes in the expression and assembly of tight junction proteins in cultured primary kidney endothelial cells. In the context of I/R kidney injury, Objective III will examine endothelial leakage to macromolecules, kidney inflammation and function after kidney endothelium-specific or macrophage-specific overexpression or deletion of STC1. Few therapeutic options are currently available for acute kidney injury (AKI). Our data identify STC1 as a potential therapeutic target for ischemic injury in the kidney and other organs, and our proposed studies will further elucidate STC1 mechanisms of action.
-
Stanniocalcin-1, a novel anti-inflammatory protein
#R01DK080306 - $1,738,389.00 (08/01/2009 - 07/31/2015)
- Grant funding from NIH
- Macrophages are important mediators of inflammation. Our data show stanniocalcin-1 (STC1) decreases macrophage response to chemoattractants and migration across an endothelial monolayer. STC1 also diminishes superoxide generation in macrophages, by inducing uncoupling protein-2 (UCP2), and inhibits the NF-B pathway. In cultured endothelial cells, STC1 inhibits cytokine-induced changes in permeability and tight junction protein expression. STC1 transgenic mice, which exhibit elevated serum levels and preferential expression of STC1 in macrophages and endothelium, display less inflammatory macrophages in the glomeruli during anti-glomerular basement membrane (GBM) disease, resulting in kidney protection. Overall hypothesis: STC1 suppresses inflammation through inhibition of macrophage recruitment and function, and cytokine-induced increase in endothelial permeability. In Specific Aim I, we will determine mechanisms of UCP2 upregulation by STC1 and the role of superoxide in STC1-mediated inhibition of NF-B in macrophages. In Specific Aim II, we will determine the effect of STC1 on cytokine–induced changes in expression and assembly of tight junction proteins in cultured primary kidney endothelial cells. In Specific Aim III, in the context of anti-GBM disease, we will examine endothelial permeability of native kidney vessels, as well as kidney inflammation and function, after kidney endothelium-specific or macrophage-specific overexpression or deletion of STC1.
Languages
Hebrew, Arabic
to edit your profile